Metastatic Prostatic Adenocarcinoma in Patient With Muir-Torre Syndrome Misdiagnosed as Metastatic Sebaceous Carcinoma: Case Report and Systematic Literature Review.


Journal

The American Journal of dermatopathology
ISSN: 1533-0311
Titre abrégé: Am J Dermatopathol
Pays: United States
ID NLM: 7911005

Informations de publication

Date de publication:
Sep 2020
Historique:
pubmed: 23 6 2020
medline: 6 7 2021
entrez: 23 6 2020
Statut: ppublish

Résumé

Muir-Torre syndrome (MTS) is a rare autosomal dominant condition characterized by the presence of at least one cutaneous sebaceous tumor and one visceral malignancy, arising mostly from the gastrointestinal tract. We present the case of a 63-year-old man with several cutaneous and visceral neoplasias in the context of MTS, and a pelvic lymph node lesion diagnosed initially as metastatic sebaceous carcinoma, but later identified as metastasis from a newly diagnosed prostatic adenocarcinoma. Histological similarities between these 2 lesions are discussed. A systematic literature review was conducted evaluating all published cases of patients with MTS in which metastases were reported. Eighteen articles were included in the final synthesis, representing 20 patients with a total of 26 metastases. Seventeen patients (85%) exhibited metastases originating from MTS-related neoplasms, whereas only 2 patients (11%) exhibited metastases from concomitant malignancies. Of the 85% of patients with metastases from MTS-related malignancies, most originated from noncutaneous sources (78% from visceral neoplasms and 22% from sebaceous carcinomas). When stratifying according to metastases, 23 cases (88%) originated from MTS-related lesions, whereas only 3 (12%) originated from unrelated malignancies. Our findings thus demonstrate that most metastases found in MTS patients (88%) do indeed originate from MTS-related neoplasms. Nevertheless, it remains imperative that a broad differential diagnosis is maintained when assessing a novel lesion, to avoid misdiagnoses, as in the present case, with significant therapeutic and prognostic implications.

Identifiants

pubmed: 32568842
doi: 10.1097/DAD.0000000000001633
pii: 00000372-202009000-00013
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Case Reports Journal Article Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

700-705

Références

Muir EG, Bell AJ, Barlow KA. Multiple primary carcinomata of the colon, duodenum, and larynx associated with kerato-acanthomata of the face. Br J Surg. 1967;54:191–195.
Torre D. Multiple sebaceous tumors. Arch Dermatol. 1968;98:549–551.
Carethers JM, Stoffel EM. Lynch syndrome and Lynch syndrome mimics: the growing complex landscape of hereditary colon cancer. World J Gastroenterol. 2015;21:9253–9261.
Navi D, Wadhera A, Fung MA, et al. Muir-Torre syndrome. Dermatol Online J. 2006;12:4.
Peltomaki P, Vasen HF. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology. 1997;113:1146–1158.
John AM, Schwartz RA. Muir-Torre syndrome (MTS): an update and approach to diagnosis and management. J Am Acad Dermatol. 2016;74:558–566.
Cho NY, Choi M, Kim BH, et al. BRAF and KRAS mutations in prostatic adenocarcinoma. Int J Cancer. 2006;119:1858–1862.
Cornejo KM, Hutchinson L, Deng A, et al. BRAF/KRAS gene sequencing of sebaceous neoplasms after mismatch repair protein analysis. Hum Pathol. 2014;45:1213–1220.
Schwartz RA, Torre DP. The Muir-Torre syndrome: a 25-year retrospect. J Am Acad Dermatol. 1995;33:90–104.
Buitrago W, Joseph AK. Sebaceous carcinoma: the great masquerader: emgerging concepts in diagnosis and treatment. Dermatol Ther. 2008;21:459–466.
Kyllo RL, Brady KL, Hurst EA. Sebaceous carcinoma: review of the literature. Dermatol Surg. 2015;41:1–15.
Narita H, Kanzaki T, Yokota M, et al. Muir-Torre syndrome. J Dermatol. 1992;19:105–108.
Demirci H, Nelson CC, Shields CL, et al. Eyelid sebaceous carcinoma associated with Muir-Torre syndrome in two cases. Ophthalmic Plast Reconstr Surg. 2007;23:77–79.
Honchel R, Halling KC, Schaid DJ, et al. Microsatellite instability in Muir-Torre syndrome. Cancer Res. 1994;54:1159–1163.
Chang TW, Weaver AL, Brewer JD. Sebaceous carcinoma in the clinical setting of non-Hodgkin lymphoma: the Mayo Clinic experience. Int J Dermatol. 2013;52:1210–1214.
Iacobelli J, Harvey NT, Wood BA. Sebaceous lesions of the skin. Pathology. 2017;49:688–697.
Cutaneous Adnexal Tumors. Philadelphia, PA: Wolters Kluwer Health; 2012.
Compton LA, Murphy GF, Lian CG. Diagnostic immunohistochemistry in cutaneous neoplasia: an update. Dermatopathology (Basel). 2015;2:15–42.
Harvey NT, Budgeon CA, Leecy T, et al. Interobserver variability in the diagnosis of circumscribed sebaceous neoplasms of the skin. Pathology. 2013;45:581–586.
Kazakov DV, Calonje E, Rutten A, et al. Cutaneous sebaceous neoplasms with a focal glandular pattern (seboapocrine lesions): a clinicopathological study of three cases. Am J Dermatopathol 2007;29:359–364.
Begnami MD, Quezado M, Pinto P, et al. Adenoid cystic/basal cell carcinoma of the prostate: review and update. Arch Pathol Lab Med. 2007;131:637–640.
Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;25:276–308.
Fahmy A, Burgdorf WH, Schosser RH, et al. Muir-Torre syndrome: report of a case and reevaluation of the dermatopathologic features. Cancer. 1982;49:1898–1903.
Paner GP, Luthringer DJ, Amin MB. Best practice in diagnostic immunohistochemistry: prostate carcinoma and its mimics in needle core biopsies. Arch Pathol Lab Med. 2008;132:1388–1396.
Dominguez-Valentin M, Joost P, Therkildsen C, et al. Frequent mismatch-repair defects link prostate cancer to Lynch syndrome. BMC Urol. 2016;16:15.
Guedes LB, Antonarakis ES, Schweizer MT, et al. MSH2 loss in primary prostate cancer. Clin Cancer Res. 2017;23:6863–6874.
Pritchard CC, Morrissey C, Kumar A, et al. Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer. Nat Commun. 2014;5:4988.
Abbott JJ, Hernandez-Rios P, Amirkhan RH, et al. Cystic sebaceous neoplasms in Muir-Torre syndrome. Arch Pathol Lab Med. 2003;127:614–617.
Bassetto F, Baraziol R, Sottosanti MV, et al. Biological behavior of the sebaceous carcinoma of the head. Dermatol Surg. 2004;30:472–476.
Baumgartner E, Ullman D, Jones JA, et al. Postradiation histiocytic sarcoma in the setting of muir-torre syndrome. Case Rep Pathol. 2018;2018:5947870.
Becker-Schiebe M, Hannig H, Hoffmann W, et al. Muir-Torre syndrome—an uncommon localization of sebaceous carcinomas following irradiation. Acta Oncol. 2012;51:265–268.
Davis DA, Cohen PR. Genitourinary tumors in men with the Muir-Torre syndrome. J Am Acad Dermatol. 1995;33:909–912.
Hadravsky L, Kazakov DV, Stehlik J, et al. Aggressive extraocular sebaceous carcinoma of the scalp involving the brain in a patient with muir-torre syndrome. Am J Dermatopathol. 2016;38:618–622.
Ishiguro Y, Homma S, Yoshida T, et al. Usefulness of PET/CT for early detection of internal malignancies in patients with Muir-Torre syndrome: report of two cases. Surg Case Rep. 2017;3:71.
Kurtzman DJ, Fabiano AJ, Qiu J, et al. Muir-torre syndrome and central nervous system malignancy: highlighting an uncommon association. Dermatol Surg. 2015;41:856–859.
Nair N, Curtin JP, Mittal K, et al. Cervical adenocarcinoma in a patient with Lynch syndrome, Muir-Torre variant. J Clin Oncol. 2012;30:e5–e6.
Pancholi A, Collins D, Lindley R, et al. Muir-Torre syndrome: a case report and screening recommendations. Ann R Coll Surg Engl. 2008;90:W9–W10.
Paraf F, Sasseville D, Watters AK, et al. Clinicopathological relevance of the association between gastrointestinal and sebaceous neoplasms: the Muir-Torre syndrome. Hum Pathol. 1995;26:422–427.
Smith J, Crowe K, McGaughran J, et al. Sebaceous adenoma arising within an ovarian mature cystic teratoma in Muir-Torre syndrome. Ann Diagn Pathol. 2012;16:485–488.
Southey MC, Young MA, Whitty J, et al. Molecular pathologic analysis enhances the diagnosis and management of Muir-Torre syndrome and gives insight into its underlying molecular pathogenesis. Am J Surg Pathol. 2001;25:936–941.
Spraul CW, Lang GE, Grossniklaus HE, et al. Metastatic adenocarcinoma to the retina in a patient with Muir-Torre syndrome. Am J Ophthalmol. 1995;120:248–250.
Tailor IK, Cook J, Reilly JT, et al. Acute myeloid leukaemia associated with Muir-Torre variant of hereditary non-polyposis colon cancer (HNPCC): implications for inherited and acquired mutations in DNA mismatch repair genes. Br J Haematol. 2012;156:289–291.
Vernez M, Hutter P, Monnerat C, et al. A case of Muir-Torre syndrome associated with mucinous hepatic cholangiocarcinoma and a novel germline mutation of the MSH2 gene. Fam Cancer. 2007;6:141–145.
Warschaw KE, Eble JN, Hood AF, et al. The Muir-Torre syndrome in a black patient with AIDS: histopathology and molecular genetic studies. J Cutan Pathol. 1997;24:511–518.
Yozu M, Symmans P, Dray M, et al. Muir-Torre syndrome-associated pleomorphic liposarcoma arising in a previous radiation field. Virchows Archiv. 2013;462:355–360.

Auteurs

Leila Cattelan (L)

Faculty of Medicine, McGill University, Montreal, Québec, Canada.

Jad Abi-Rafeh (J)

Faculty of Medicine, McGill University, Montreal, Québec, Canada.

Fadi Brimo (F)

Department of Pathology, McGill University Health Centre, Montreal, Québec, Canada.

Roy Kazan (R)

Division of Plastic and Reconstructive Surgery & Division of Experiential Surgery, Department of Surgery, McGill University Health Centre, Montreal, Québec, Canada; and.

Margaret Redpath (M)

Department of Pathology, Jewish General Hospital, Montreal, Québec, Canada.

May Chergui (M)

Department of Pathology, McGill University Health Centre, Montreal, Québec, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH